CIK 0001434647 · Non-accelerated filer<br>Smaller reporting company
ZEVRA THERAPEUTICS, INC.
Sign in to watch- Ticker
- ZVRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205894398
- Phone
- (888) 958-1253
- Business address
- 101 FEDERAL STREET, BOSTON, MA, 02110
- Former names
- KEMPHARM, INC, KEMPHARM INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $224,948
- in 1 filing, $225K under 10b5-1 plans
Net −$224,948. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-14 | McFarlane Neil F. President and CEO | Sale 10b5-1 | −30,544 | $8.05 | $246K | 191,516 |
| 2025-02-13 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Sale 10b5-1 | −3,000 | $7.86 | $24K | 16,341 |
| 2025-02-13 | Schafer Joshua CCO & EVP, Bus. Development | Sale 10b5-1 | −10,500 | $7.86 | $83K | 29,486 |
| 2025-02-13 | Clifton R. LaDuane CFO & Treasurer | Sale 10b5-1 | −11,000 | $7.86 | $86K | 51,361 |
| 2025-02-13 | McFarlane Neil F. President and CEO | Sale 10b5-1 | −61,273 | $7.86 | $481K | 222,060 |
| 2025-02-07 | McFarlane Neil F. President and CEO | Grant or award · Stock Option (right to buy) | +225,000 | 225,000 | ||
| 2025-02-07 | McFarlane Neil F. President and CEO | Grant or award · Restricted Stock Unit | +112,500 | 112,500 | ||
| 2025-01-31 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Option exercise | +11,666 | 19,341 | ||
| 2025-01-31 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Option exercise · Restricted Stock Unit | −11,666 | 23,334 | ||
| 2025-01-31 | Schafer Joshua CCO & EVP, Bus. Development | Option exercise | +35,333 | 39,986 | ||
| 2025-01-31 | Schafer Joshua CCO & EVP, Bus. Development | Option exercise · Restricted Stock Unit | −35,333 | 70,667 | ||
| 2025-01-31 | Clifton R. LaDuane CFO & Treasurer | Option exercise | +43,333 | 62,361 | ||
| 2025-01-31 | Clifton R. LaDuane CFO & Treasurer | Option exercise · Restricted Stock Unit | −43,333 | 86,667 | ||
| 2025-01-31 | McFarlane Neil F. President and CEO | Option exercise | +233,333 | 283,333 | ||
| 2025-01-31 | McFarlane Neil F. President and CEO | Option exercise · Restricted Stock Unit | −233,333 | 466,667 | ||
| 2025-01-30 | Quartel Adrian W Chief Medical Officer | Grant or award · Stock Option (right to buy) | +68,000 | 68,000 | ||
| 2025-01-30 | Quartel Adrian W Chief Medical Officer | Grant or award · Restricted Stock Unit | +34,000 | 34,000 | ||
| 2025-01-30 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Grant or award · Stock Option (right to buy) | +38,000 | 38,000 | ||
| 2025-01-30 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Grant or award · Restricted Stock Unit | +19,000 | 19,000 | ||
| 2025-01-30 | Thompson Rahsaan Chief Legal & Compliance | Grant or award · Stock Option (right to buy) | +68,000 | 68,000 |
Page 5 of 9 · 166 trades